ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients with unresectable advanced/recurrent gastric cancer who are confirmed to have HER2 overexpression and started treatment with this drug*
- Patients who receive this drug* for the first time after this drug* is launched * Not including the biological product, HERCEPTIN, and biosimilars of HERCEPTIN other than this drug
- not specified in this study
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Adachi-ku, Tokyo,
- Anjo-city,
- Aomori-shi,
- Chiba-shi,
- Chiba,
- Chikushino-shi,
- Fukuoka,
- Fukuroi-shi,
- Funai-gun,
- Hiroshima-shi,
- Hiroshima,
- Ichihara-shi,
- Kanagawa,
- Kanazawa-shi,
- Kisaradu-shi,
- Kitaadachi-gun,
- Koto-ku, Tokyo,
- Kyoto,
- Misawa-shi,
- Morioka-shi,
- Nagasaki,
- Nagoya City,
- Nagoya,
- Oomura City,
- Osaka-si,
- Osaka-si,
- Sagamiharashi,
- Saga,
- Sapparo City,
- Sapporo City,
- Sapporo-shi,
- Sapporo-shi,
- Sasebo-shi,
- Sendai-shi,
- Sendai-shi,
- Shizuka,
- Shizuoka-shi,
- Sizuoka-shi,
- Takatuki-si,
- Tsuchiura-shi,
- Tsukuba-shi,
- Uji-shi,
- Yamagata-shi,
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title | Safety and Efficacy of Trastuzumab BS | ||||
Official Title | TRASTUZUMAB BS for Intravenous Infusion 60 mg [Pfizer], TRASTUZUMAB BS for Intravenous Infusion 150 mg [Pfizer] General Investigation (Unresectable Advanced/Recurrent HER2-Overexpressing Gastric Cancer) | ||||
Brief Summary | To confirm the safety and efficacy of this drug under the actual use | ||||
Detailed Description | Not Provided | ||||
Study Type | Observational | ||||
Study Design | Observational Model: Case-Only Time Perspective: Prospective | ||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Probability Sample | ||||
Study Population | 100 patients | ||||
Condition | Gastric Cancer | ||||
Intervention | Not Provided | ||||
Study Groups/Cohorts | Not Provided | ||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status | Not yet recruiting | ||||
Estimated Enrollment | 150 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | February 6, 2023 | ||||
Estimated Primary Completion Date | February 6, 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: - not specified in this study | ||||
Sex/Gender |
| ||||
Ages | Child, Adult, Older Adult | ||||
Accepts Healthy Volunteers | No | ||||
Contacts |
| ||||
Listed Location Countries | Not Provided | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT04181333 | ||||
Other Study ID Numbers | B3271007 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product | Not Provided | ||||
IPD Sharing Statement |
| ||||
Responsible Party | Pfizer | ||||
Study Sponsor | Pfizer | ||||
Collaborators | Not Provided | ||||
Investigators |
| ||||
PRS Account | Pfizer | ||||
Verification Date | December 2020 |